-
Alize-anrs was a 48 week randomized controlled trial in which 355 virologically-suppressed, HIV-infected patients receiving PIs were randomized to a continuation regimen containing EFV vs PI.
-
As we plunge into the late summer months, thoughts turn again to West Nile Virus. July and August are typically the hottest months for WNV. As of the end of June, 22 states in the continental United States have reported avian, animal, or mosquito WNV infections for the year.
-
Treating Chronic Primary Insomnia; New Breakthrough in Smoking Cessation?; FDA Actions
-
King and colleagues conducted prospective, laboratory-based surveillance of all community-onset staphylococcal skin and soft-tissue infections presenting to Grady Memorial Hospital and its affiliated clinics for a 3.5-month period in 2003.
-
The rapidly evolving epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) colonization and infection has resulted in ambiguity in the designation of individual instances as either community or health care associated. This essay represents a proposal for a telegraphic system of unambiguous description of isolates.
-
Posaconazole exhibits numerous advantages over other triazoles in regards to drug-drug interactions, bioavailability issues, and its side-effect profile.
-
Due to the long half-lives of nevirapine and efavirenz, it is now recommended that when non-nucleoside reverse transcriptase inhibitor (nnRTI)-containing antiretroviral regimens are discontinued, backbone nucleoside analogs should be continued for 4-7 days to reduce the likelihood of development of nnRTI resistance.
-
In October 2005, the American Committee on Immunization Practices provided provisional recommendations for the acellular pertussis vaccine (Tdap) (ADACELTM, Sanofi Pasteur) as a single booster dose for persons 11-64 years of age.
-
The STAR Trial (Tamoxifen and Raloxifene); FDA Actions
-
The CDC identified 17 patients with community-acquired pneumonia (CAP) due to S. aureus by following up on reports from the Emerging Infections Network of the Infectious Disease Society of America (IDSA) during the 2003-2004 influenza season.
